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Abstract 
Background: To study the immediate and long 
term success of Direct Current (DC) Cardioversion 
for persistent non-valvular atrial fibrillation.  
Methods: In this prospective study 200 patients 
with persistent non-valvular atrial fibrillation 
presenting to arrhythmia clinics  were selected. They 
were anticoagulated to INR of 2-3, a transesophageal 
echocardiogram was performed 3 weeks later to rule 
out left atrial thrombus and then patients were 
subjected to external electrical cardioversion. 
Patients were followed up 3 monthly for a total 
period of 3 years to assess maintenance of sinus 
rhythm.  
Results: The mean age of study population was 69 
years and 65.5% were male. Immediate success was 
achieved in 65.5% patients. At 3 months 54.5% were 
in sinus rhythm and this percentage dropped to 
43.5% at 6 months.185 patients completed 1 year 
follow up and 28.5% were found to be in sinus 
rhythm. At 2 years 172 patients reported out of which 
19.50% were still in sinus rhythm. In relation to the 
LA size immediate success was achieved in 58.01% 
with size less than 4cm, 35.11% with LA size 
between 4 to 4.5cm and only in 6.8% with LA size 
greater than 4.5cm. This trend was maintained in 
long term as well. And in relation to drugs those on 
amiodarone had best success. Complications were 
encountered in two patients, one patient had 
transient ischemic attack and other suffered 
bradycardia needing temporary pacing.   
Conclusion: DC cardioversion for rhythm control 
in atrial fibrillation is a safe and effective treatment 
strategy with reasonable short term success and 
although limited but meaningful long term success. 
Key Words: Atrial fibrillation, Rhythm control, 
Electrical cardioversion, Left atrial size. 
 
Introduction 
 Rhythm control for atrial fibrillation has theoretical 
advantages associated and can be a beneficial 
approach in selected population Atrial fibrillation (AF) 
is the most common sustained arrhythmia.1,2  It is 
associated with high health care costs and a high 
morbidity and almost doubled mortality.3,4  Since its 
prevalence being high in older age it is thought to be 
an increasing health care problem as people live longer 
because of better health care.5 
The two management strategies for atrial fibrillation 
that is rate and rhythm control have been intensely 
investigated over the past two decades  and not much 
difference was found in the end points of mortality 
and morbidity, however there are still some issues to 
be resolved. 2,6-8  Some controversies are linked to these 
trials.Study population consisted of older and at high 
risk for stroke(Atrial Fibrillation Followup 
Investigation of Rhythm Management;AFFIRM ), one 
prior cardioversion and recurrence of atrial 
fibrillation( RACE ), thus results cannot be generalized 
to all AF populations.1,9 Secondly the maximum follow 
up was up to 3.5 years.1,3 Mortality rates were actually 
found to decrease after 5 years in rhythm control 
strategy.3 Mortality benefit in rhythm control was also 
supported by Danish Investigation of Arrhythmia and 
Mortality on Dofetilide (DIAMOND) and on treatment 
analysis of AFFIRM.2  Lastly the beneficial effects of 
rhythm control might have been offset by the reduced 
efficacy and toxicity of antiarrhythmic drugs. Even in 
these trials comparable efficacy of the two strategies 
had moderate strength of evidence.3 
Theoretical benefits have been associated with rhythm 
control like improved cardiac performance, prevention 
of thromboembolism and tachycardia induced 
cardiomyopathy.4,9 Sinus rhythm maintenance may be 
favoured owing to disruption or reversal of adverse 
atrial remodeling, improved exercise tolerance and 
quality of life. 2,6,8,11  It may be the preferred approach 
in younger patients, extremely symptomatic patients 
and patients with heart failure.3,9 
Rhythm control by electrical cardioversion is more 
effective than pharmacological cardioversion with 
upto 90-95% success depending upon patient 
selection.12,13,14  In external cardioversion biphasic 
waveform is superior to monophasic.3,15 Our study 
aims to find the immediate and long term success rates 
of direct current cardioversion (DCCV) for persistent 
non valvular AF in Asian population particularly 
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subcontinent.  Purpose is to encourage the use of 
rhythm control strategy where appropriate. 
 
Patients and Methods 
This study was a prospective study and was 
performed at the Armed Forces Institute of 
Cardiology. The study included 200 consecutive 
patients undergoing cardioversion for persistent atrial 
fibrillation from May 2012 to May 2016. All patients 
were seen in arrhythmia clinic in Armed Forces 
Institute of Cardiology, placed on anticoagulant 
(Warfarin) and INR was maintained between 2–3 for at 
least 3 weeks prior to electrical cardioversion. All 
patients were subjected to transesophageal 
echocardiogram (TOE) after three weeks to rule out 
the presence of any thrombus in the left atrium, prior 
to DCCV. And warfarin was continued for 4 weeks 
post DCCV.  Protocol for DC -Cardio –Version 
(DCCV): The procedure was carried out in the cardiac 
emergency or coronary care unit after obtaining a 
formal written informed consent. The patients were 
fasting overnight, premedicated with I/V Midazolam 
and Nalbuphine. Synchronized Cardioversion was 
carried out with a M-series Zoll biphasic defibrillator. 
We used non-escalating energy protocol (200J, 200J, 
200J). If unsuccessful, then single shock of 200J with 
paddles in the anteroposterior position on precordium 
was attempted. Post DCCV, the patients were detained 
for 04 hours and discharged if stable. Immediate 
success was defined as successful conversion to sinus 
rhythm, documented on ECG.The patients were 
followed up on 03 monthly basis in the arrhythmia 
clinic. They were subjected to an electrocardiogram, an 
echocardiogram and Prothrombin time/INR on every 
visit.All patients were subjected to transthoracic 
echocardiogram and all the parameters were recorded. 
Left Atrial (LA) size was calculated (Normal range 
considered was less than 4.0 cm). Ejection fraction was 
also calculated and so was any other abnormality. 
Results 
The mean age was 69 ± 2 years (range: 30-75 years). In 
the study group, 09 (15.51%) patients had previously 
undergone coronary artery bypass grafting (CABG), 38 
(65.51%) patients were diabetic and 34 (58.62%) 
patients hypertensive (Table 1).Immediate success was 
achieved in 65.5%, out of which 68.7% were males and 
41 (31.29%) were females. At 3 months follow up, 198 
patients reported, 109(54.5%) patients were in sinus 
rhythm, in which 72 were males and 37 were females. 
At 6 months follow up, 194 patients (51 Male, 36 
Female) reported, out of which 87(43.5%) patients 
were in sinus rhythm. At 1 year, 185 (33 Male, 24 
Females) patients reported, 57(28.50%) patients were 
in sinus rhythm (SR).One hundred and seventy two  
patients (21 males and 18 females) completed follow 
up for 2 years, of which 39 (19.50%) patients were still 
in sinus rhythm. DCCV was carried out for a second 
time in 08 patients on recurrence of atrial fibrillation. 
Out of them, 6 patients were in SR at end of 1 year 
follow up (Table 1). 
 
Table 1:Summary of sinus rhythm maintenance 
Follow up 
schedule 
Immediate 
success 
At 03 
months 
At 06 
month
s 
01  
year 
02 
yea
rs 
03 
years 
Maintenance 
of sinus 
rhythm 
131  
(65.5%) 
109 
(54.5%) 
87 
(43.5%
) 
57 
(28.5
0%) 
39 
(19.
50
%) 
21 
(10.50
%) 
Lost to follow 
up 
0 2 4 9 13 19 
 
Of the 131 patients in whom immediate success was 
achieved 76 (58.01%) patients had LA size less than 4.0 
cm, while DC cardio version was successful in only 09 
(6.8%) patients with LA size of more than 4.5 cm. At 06 
months follow up, out of 87 patient in SR, 54 (62.06%) 
patients had left atrial size in normal range. At three 
years out of 21 patients (10.50%) in sinus rhythm, 18 
(85.71%) were those having LA size less than 4.0 cm, 
while no patient with LA size greater than 4.5 cm was 
in sinus rhythm (Table 2). 
 
Table 2:Distribution of patients maintaining 
sinus rhythm according to LA size 
Left atrial 
size 
Total No. 
of 
patients 
(200) 
Immedia
te 
Success 
(131) 
At 03 
months 
(109) 
06  
months 
(87) 
01 
 year 
(57) 
02  
years 
(39) 
03 
 years 
(21) 
 
Less than 
4.0cm 
110 
76 
(58.01%) 
65 
(59.63%) 
54 
(62.06%) 
46 
(80.70%) 
32 
(82.05%) 
18 
(85.71%) 
4.0-4.5cm 60 
46 
(35.11%) 
36 
(33.02%) 
29 
(33.33%) 
11 
(19.29%) 
07 
(17.19%) 
03 
(14.25%) 
More than 
4.5 cm 
30 
 
09 (6.8%) 
 
08 (6.1%) 04(4.5%) 0 0 0 
 
The patients were on various medications before 
enrollment into study. Most common drug used was 
Beta Blockers group (39.6%), 31.3% were on 
Amiodarone in, 15% were on combination of 
amiodarone and digoxin, and 14.1% of patients no 
clear idea of the exact drug taken during last 03 
months could be obtained.In patients on amiodarone, 
there was 100% immediate success (62 out of 62). Of 
those, who continued taking maintenance dose of 
amiodarone, 52 (83.87 %) remained in SR at the end of 
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03 months and 33 (53.22%) remained in SR at the end 
of 06 months. One patient developed severe 
bradycardia and asystole, which necessitated 
temporary pacemaker and assisted ventilation. 
However, sinus rhythm returned after three days. 
Another patient had transient weakness of left arm for 
a few hours a day after DCCV. 
 
Discussion 
Our success rates in terms of immediate conversion to 
sinus rhythm are comparable to the previous studies, 
however we demonstrated better results in 
maintenance of sinus rhythm in long term, which may 
be attributed to the fact that we had sizeable amount 
of serving military personal (all male and relatively 
young with normal left atrial sizes) in our study 
population. 15 
Dilated and fibrosed left atrium (LA) provide 
substrate for reentry necessary for AF generation. 1 AF 
also causes electrical and structural remodeling of left 
atrium leading to its sustainability and recurrence.1 
Early cardioversion leads to atrial size reduction and 
restores atrial contractility.1 LA volume indexed to 
body surface area (LAVI) has been shown to be 
superior in predicting recurrence of nonvalvular AF 
after successful cardioversion.21-24 In our setup because 
of limited experience and more time consuming 
method for LA volume measurement, one-
dimensional/linear LA sizes measured which despite 
some limitations is reproducible and has been shown 
to correlate with both CMR and angiographic 
measurement.20 In this study, LA size was negatively 
correlated to the success in sinus rhythm maintenance 
just like in previous studies.7,15-19 
Pretreatment with antiarrhythmic drug enhances 
restoration and maintenance of sinus rhythm after 
electrical cardioversion and especially amiodarone has 
been shown to be the most effective.15 In this study 
patients who were on amiodarone had best success 
both in immediate achievement and long term 
maintenance of sinus rhythm. So we report similar 
results to previous work on patients undergoing 
DCCV for persistent AF.25,26 
AF duration has also been related to the outcomes of 
cardioversion.15 In our study we also observed that 
patients with shorter duration of AF had better results 
in terms of sinus rhythm maintenance.The trends of 
sinus rhythm achievement were similar in both 
preserved and reduced LV ejection fraction (EF) in our 
study and all patients experience symptomatic 
improvement as assessed subjectively.  
In view of improvement of EF with sinus rhythm 
achievement and favorable results in NYHA class and 
QOL in patients with reduced EF and heart failure we 
support the use of rhythm control in heart failure 
patients both with reduced and preserved EF.3, 10, 27 
Non-escalating protocol and use of biphasic 
waveforms have been shown superior in 
cardioversion.3,16,27 We used non escalating energy 
protocol with impedance compensated biphasic 
waveform in this study. 
Though generally DCCV has been considered a safe 
procedure, a few complications have been attributed 
like thromboembolic risk and electrical complications 
such as asystole or bradycardia. Thromboembolic 
stroke was linked to rhythm control as to AFFIRM 
(occurred where anticoagulation was stopped in high 
risk study population, which now is recommended to 
continue in this group).1 
The rates of thromboembolism are equal in both 
electrical and pharmacological cardioversion.4 Stroke 
risk few weeks post cardioversion is 5% which is 
equivalent to the yearly stroke risk in AF population.4 
In previous studies, thromboembolism has been 
shown to be reduced markedly by anticoagulation 
prior to cardioversion and 4 weeks afterwards (to 
compensate for atrial stunning) and so did the use of 
TOE to exclude LA thrombus.4 We also performed 
TOE in all patients and continued with anticoagulation 
after successful cardioversion for 4 weeks irrespective 
of CHADVASC score.  
We did not encounter any stroke in our study though 
one patient had transient ischemic attack on second 
day which recovered fully. This occurred despite 
adequate anticoagulation and preprocedure Trans 
Oesophageal Echocardiograph (TOE) had not revealed 
any intracardiac thrombus. Another patient developed 
severe bradycardia and asystole requiring temporary 
pacing. That patient regained sinus rhythm, however 
on subsequent workup she was found to have sinus 
node dysfunction. The overall incidence of 
complications is low and should not be used to justify 
withholding rhythm control efforts in patients who 
might benefit from it. 
In present study surface ECG was used ,on follow up 
visits, to find out AF status and hence might have 
underestimated the paroxysmal AF occurrence 
however we would Holter monitor in patients who 
would complain of palpitations and other symptoms, 
in between. We could not assess symptomatic 
improvement objectively in the earlier part of study, 
however later on we started collecting that data as 
well. A substantial proportion of study population 
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were from poorer socioeconomic group, hence follow 
up was limited by financial difficulties and 
transportation problem. 
Conclusion 
1.DC cardioversion is safe and effective way of 
restoring sinus rhythm in carefully selected patients 
with non valvular persistent AF. 
2.Younger patients with new onset AF should be 
subjected to DCCV cardioversion as they have the best 
chance of maintaining sinus rhythm in long term.    
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